yingweiwo

PLK

PLK

Polo-like Kinases (PLKs) are a family of highly conserved serine/threonine protein kinases that are essential for a variety of biological functions, including cell division and mitosis checkpoint regulation. Five PLKs (PLK 1-5) play a variety of roles in DNA damage response, intra-S-phase and G2/M checkpoints, spindle formation, and centrosome dynamics in mammals.

PLKs are distinguished by their Polo-box domain, which mediates protein interactions. Depending on the biological context, they are also regulated by transcription, proteolysis, and phosphorylation. PLKs are now understood to function in differentiated cells and link cell division to developmental processes.

PLK related products

Structure Cat No. Product Name CAS No. Product Description
(E/Z)-Rigosertib sodium V1575 (E/Z)-Rigosertib sodium 1225497-78-8 (E/Z)-Rigosertib sodium (formerly known as ON-01910; ON01910; Estybon), the sodium salt ofRigosertib, is a novel, potent and non-ATP-competitive inhibitor of PLK1 with potential anticancer activity.
3MB-PP1 V60036 3MB-PP1 956025-83-5 3MB-PP1 is a bulky purine analog that is a Polo-like kinase 1 (Plk1) inhibitor.
BI 2536 V1573 BI 2536 755038-02-9 BI2536 (BI-2536; BI 2536) is a novel PLK1/BRD4 dual inhibitor with potential antitumor activity.
BI2536-PEG2-Halo V99755 BI2536-PEG2-Halo BI2536-PEG2-Halo is a bifunctional molecule consisting of a Halo-tagged ligand and the Polo-like kinase 1 (PLK1) inhibitor BI-2536.
BTO-1 V52314 BTO-1 40647-02-7 BTO-1 is a Polo-like kinase (Plk) inhibitor.
CD 10899 V88745 CD 10899 1331770-20-7 CD 10899 is a hydroxylated metabolite of Volasertib.
Centrinone V17894 Centrinone 1798871-30-3 Centrinone (LCR263; LCR-263; LCR 263) is a novel and potent inhibitor of polo-like kinase 4 (PLK4)with potential antineoplastic activity.
Centrinone-B V17895 Centrinone-B 1798871-31-4 Centrinone-B (LCR323; LCR-323; LCR 323) is a novel and reversible polo-like kinase 4 (PLK4) inhibitor with potential anticancer activity.
CFI-400437 HCl V2427 CFI-400437 HCl 1247000-76-5 (1E)-CFI-400437 diHCl is potent against PLK4 (IC50= 0.6 nM) and selective for other members of the PLK family (>10 μM).
CFI400945游离碱 V2729 Ocifisertib (CFI-400945) 1338806-73-7 CFI400945 is a potent, selective, and orally bioavailable PLK4 (polo-like kinase 4) inhibitor with IC50 value of 2.8 ±1.4 nM and potential antineoplastic activity.
CZS-241 V51036 CZS-241 3016297-55-2 CZS-241 is a novel Polo-like Kinase (PLK) 4 inhibitor (IC50=2.6 nM).
Dihydrobaicalein V54801 Dihydrobaicalein 35683-17-1 DiHydrobaicalein is a PLK1 inhibitor (antagonist) with IC50 of 6.3 μM.
GSK461364 V1576 GSK461364 929095-18-1 GSK-461364 (GSK461364; GSK 461364)is a novel, potent, selective, reversible and ATP-competitive small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antitumor activity.
GW843682X V4918 GW843682X 660868-91-7 GW843682X is a novel, potent, selective, ATP-competitive inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase 3 (PLK3) with IC50s of 2.2 nM and 9.1 nM, respectively.
HMN-176 V22224 HMN-176 173529-10-7 HMN-176 is an analogue of diphenylethylene that can inhibit mitosis and interfere with plk1, but has little effect on tubulin polymerization.
HMN-214 V1577 HMN-214 173529-46-9 HMN-214 (HMN 214; HMN214), stilbene derivative, is a potent and orally bioactive prodrug of HMN-176, which alters the cellular spatial orientation of Plk1 (polo-like kinase-1).
MLN0905 V1578 MLN0905 1228960-69-7 MLN0905 (MLN-0905; MLN 0905) is a novel, potent and selective small-molecule inhibitor of polo-like kinase-1 (PLK1) with potential antineoplastic activity.
PLK1-IN-10 V88743 PLK1-IN-10 2991469-21-5 PLK1-IN-10 (Compound 4Bb) is an orally available PLK1 PBD (polo-box domain) inhibitor.
PLK1-IN-2 V55106 PLK1-IN-2 2640254-52-8 PLK1-IN-2 is a PLK1 kinase inhibitor (antagonist) with IC50 of 0.384 μM.
PLK1-IN-5 V55107 PLK1-IN-5 1001343-34-5 PLK1-IN-5 is a potent PLK1 inhibitor (antagonist) with IC50 < 500 nM.
Contact Us